Lista de obras -

Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection

artículo científico publicado en 2020

Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis

artículo científico publicado en 2019

Comparison of (99m)Tc-HEPIDA and (99m)Tc-MBrIDA from the standpoint of hepatic clearance determination-- preliminary communication

artículo científico publicado en 2009

Diagnostic value of optimised real-time sonoelastography in the assessment of liver fibrosis in chronic hepatitis B and C.

artículo científico publicado en 2016

Efficacy and direct costs of chronic hepatitis C treatment with first generation NS3/4A protease inhibitors in a real life population

artículo científico publicado en 2016

Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study

artículo científico publicado en 2016

Epidemiology of hepatitis C virus infections in Łódzkie voivodeship

artículo científico publicado en 2016

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study

artículo científico publicado en 2021

HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study

artículo científico publicado en 2022

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study

artículo científico publicado en 2022

Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?

artículo científico publicado en 2018

Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all HCV infected patients in the real-world experience?

artículo científico publicado en 2020

Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA

artículo científico publicado en 2020

Polish multicenter study on safety and efficacy of adefovir dipivoxil in the treatment of lamivudine resistant chronic hepatitis B in adults (HEP 2008)

artículo científico publicado el 1 de enero de 2011

Prevalence of HCV genotypes in Poland - the EpiTer study

artículo científico publicado en 2016

Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.

artículo científico publicado en 2019

Ribavirin priming has no beneficial effects for chronic hepatitis C patients.

artículo científico publicado en 2014

Sofosbuvir/velpatasvir in treatment-experienced HCV-infected patients - short report

scientific article published on 17 February 2020

The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study

scholarly article by Ewa Janczewska et al published 16 November 2018 in BMC Infectious Diseases

[Cardiotoxic properties of interferon: aggravation of atrio-ventricular block during treatment of chronic hepatitis C with peginterferon--a case report]

scientific article published on 01 January 2007

[Complete atrio-ventricular block as a first symptom of borreliosis: antibiotic treatment instead of pacemaker implantation]

scientific article published on 01 January 2013

Lista de obras de

Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection

Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis

Comparison of (99m)Tc-HEPIDA and (99m)Tc-MBrIDA from the standpoint of hepatic clearance determination-- preliminary communication

Diagnostic value of optimised real-time sonoelastography in the assessment of liver fibrosis in chronic hepatitis B and C.

Efficacy and direct costs of chronic hepatitis C treatment with first generation NS3/4A protease inhibitors in a real life population

Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study

Epidemiology of hepatitis C virus infections in Łódzkie voivodeship

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study

HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study

Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?

Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all HCV infected patients in the real-world experience?

Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA

Polish multicenter study on safety and efficacy of adefovir dipivoxil in the treatment of lamivudine resistant chronic hepatitis B in adults (HEP 2008)

Prevalence of HCV genotypes in Poland - the EpiTer study

Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.

Ribavirin priming has no beneficial effects for chronic hepatitis C patients.

Sofosbuvir/velpatasvir in treatment-experienced HCV-infected patients - short report

The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study

[Cardiotoxic properties of interferon: aggravation of atrio-ventricular block during treatment of chronic hepatitis C with peginterferon--a case report]

[Complete atrio-ventricular block as a first symptom of borreliosis: antibiotic treatment instead of pacemaker implantation]